Ionis (IONS)

---

---

Company Description

is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. The company’s broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. IONS’ partner, Genzyme, plans to commercialize its lead product, Kynamro, in the U.S. and Europe following regulatory approval. IONS’ patents provide strong and extensive protection for its drugs and technology.

---